ACS Medicinal Chemistry Letters · 2020 · 10 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyCancer Cell SignalingLigand BindingAntiproliferative AgentsAntiproliferative Drug ActionBromodomain InhibitionBromodomain ProteinsMyc InhibitorsProtein Binding In OncologyTherapeutic Targeting Of MycTumor Suppression Mechanisms
Bromodomain-containing protein 4 (Brd4) plays a critical regulatory role in gene transcription that has been recently recognized as a promising strategy for cancer therapy. Based on the BRD4 protein containing two tandem bromodomain structures, BD1 and BD2, we designed and synthesized a series of 3,5-dimethylisoxazole derivative dimers targeting both bromodomains simultaneously to enhance protein binding potency. Among them, compound 22 significantly inhibited the proliferation of colorectal cancer cells HCT116 (IC50 = 162 nM), with a 20-fold increase in antiproliferative activity compared to inhibitor 14. The results of WesternBlot showed that compound 22 could down-regulate c-MYC protein levels and up-regulate HEXIM1 expression and modulate apoptosis through intrinsic pathways. In addition, compound 22 exhibited outstanding antitumor efficacy in the CT-26 tumor mouse model with a tumor suppression rate of 56.1%. Taken together, 3,5-dimethylisoxazole derivative dimer 22 has remarkable protein inhibitory effect and antitumor activity in vitro and in vivo. A protein binding model of compound 22 is being further analyzed, which will facilitate the development of bivalent BRD4 inhibitors and probe the biological function of BRD4.
24
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lü, Yimin Qian, Martha Altieri et al. · Chemistry & Biology · 2015 · 1.1K citations · Full text